Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
Consider Meta (META) as the clearest bullish long mentioned, but note that no price target or timeframe was provided.
Treat CoreWeave (CRWV) as a high-risk investment: its volatile shares and elevated perceived default risk argue for caution.
Watch NVIDIA (NVDA) guidance closely; the comments were mixed, and conservative forecasts could pressure the stock.
Avoid treating Anthropic’s roughly $103–$105 futures price as fair value; no buy recommendation or valuation case was offered.
Detailed Analysis
Anthropic (private; IPO discussed)
The speaker did not apply for or receive IPO shares and said he was unsure how to value the company.
Anthropic’s reported revenue was $81 billion, with very rapid growth, but the speaker questioned whether that justified a $2 trillion valuation. He noted that reaching $200 billion in revenue soon was not obvious.
The pre-opening perpetual-futures market indicated roughly $103, and the stock opened around $104. The speaker described the futures price as about a 25% jump from the IPO price.
He expects Anthropic to raise prices, either directly or through usage-based pricing, but stressed that strong AI growth does not automatically make a stock attractive at any price.
Takeaways
Separate the company’s growth prospects from the price paid for its shares. The speaker’s core point was that even a bullish view of AI does not settle whether Anthropic’s valuation is reasonable.
The opening price and futures market were short-term trading signals, not a valuation conclusion. The speaker did not give a specific fair-value estimate or recommend buying.
NVIDIA (NVDA)
NVIDIA was the most-traded stock during the session. Its shares were down roughly 3%–4% at different points in the discussion.
The speaker said NVIDIA’s chips were the fastest, but also said the company should be valued like any other stock rather than treated as an “unsolvable” valuation case.
He thought NVIDIA might have bottomed at one point, but later expressed concern that its results could disappoint because management might give conservative guidance. He said weaker guidance would be a serious problem for the stock.
He also said NVIDIA’s guidance was a key focus for the market.
Takeaways
Pay close attention to guidance as well as reported results; the speaker suggested expectations could matter more than the current product narrative.
The discussion was mixed, not a clear buy or sell call. No price target was given.
Google / Alphabet (GOOGL)
In discussing Google’s AI models, the speaker said Gemini runs mostly on Google’s own chips rather than NVIDIA GPUs.
He described Google’s TPUs and other parallel-processing chips as GPU-like in their potential use, while acknowledging that GPUs would still be used.
Takeaways
Google’s in-house AI chips point to a potential competitive alternative to buying NVIDIA GPUs.
The transcript did not quantify the financial impact or establish how much Google’s AI infrastructure depends on its own chips.
CoreWeave (CRWV)
CoreWeave was initially up about 7%, then the speaker said it had rallied and fallen back toward $50.
In a review of credit-default-swap (CDS) spreads, he said CoreWeave had a default probability similar to Argentina’s, describing the comparison as concerning.
Takeaways
The transcript raises both share-price volatility and credit-risk concerns. Consider those risks separately from the company’s role in AI infrastructure.
The speaker did not give a price target or a direct trading recommendation.
Sellas Life Sciences (SLS)
The speaker said Sellas could not find a buyer for its stock offering and described the outcome as “sad.”
He said the company had hired J.P. Morgan for a deal, initially priced it at $13, and that the stock was around $15 at one point. He also characterized the financing as a small raise that was priced poorly.
He said the company’s prospects would become clearer when the FDA eventually makes a decision, estimating that could be about a year away.
Takeaways
The discussion highlights financing and regulatory uncertainty. A stock’s trading price above an offering price does not resolve those underlying risks.
The speaker did not make a clear buy or sell recommendation on SLS.
Insmed (INSM)
The speaker reported that Sanofi was supposedly going to acquire Insmed. Insmed rose from around $131 to $135 and was later described as halted near $140.
The acquisition was presented as a report or rumor, not a confirmed transaction.
Takeaways
Treat the reported acquisition as unconfirmed based on this discussion. A sharp move or trading halt does not establish that a deal will close.
The transcript gave no terms, timeline, or valuation for a potential acquisition.
Micron Technology (MU)
Micron was up about 4% earlier in the session.
The speaker said he was unsure whether Micron would be a good buy and mentioned that Elon Musk could compete with the company.
Takeaways
The comments point to possible competition as a factor to monitor, but the speaker did not offer a firm view on Micron’s valuation or prospects.
No price target or recommendation was given.
SanDisk (SNDK)
SanDisk was up about 6% during an early market snapshot. The speaker later remarked that it had risen around 2,000% that year, expressing surprise at the scale of the gain.
The stock was mentioned among companies that had recently been “hammered,” in the context of a possible relief rally.
Takeaways
The discussion suggests both significant recent momentum and potential volatility. A sharp rebound or large prior gain alone does not establish value.
No price target or recommendation was given.
Intel (INTC)
Intel was up about 7% in an early market snapshot and was trading below $60.
The speaker said Intel was not going bankrupt and called that outcome unlikely.
Takeaways
The speaker expressed confidence about Intel’s solvency, but did not make a broader investment case or provide a price target.
Do not read the comments as a specific buy recommendation.
Advanced Micro Devices (AMD)
AMD was up about 5% at one point.
The speaker said he liked the CEO but did not know the company well enough to express a strong view.
Takeaways
The speaker’s comments were not a stock recommendation. Further company and valuation research would be needed to form a view.
Meta Platforms (META)
The speaker said Meta “seems like a good long,” expressing a positive view.
Takeaways
This was one of the clearer bullish stock comments in the transcript, but it was not accompanied by a price target, timeline, or detailed valuation argument.
Nebius (NBIS)
Nebius was initially up about 7% in a market snapshot.
Later, the speaker called the company a “dog,” indicating a negative view.
Takeaways
The speaker’s sentiment was bearish despite the earlier share-price gain. The transcript did not explain the full investment case or provide a price target.
Robinhood Markets (HOOD)
Robinhood was described as getting “creamed” during a later market downturn.
Takeaways
The comment reflects short-term weakness, not a stated investment thesis. No target or recommendation was given.
IonQ (IONQ) and D-Wave Quantum (QBTS)
IonQ and D-Wave were described among stocks that had been “beaten to death,” then participated in a recovery-day move.
Later, the speaker said quantum stocks were down somewhat.
Takeaways
The transcript depicts sharp swings in sentiment and share prices in quantum stocks. It does not provide a company-specific view or recommendation for either stock.
These companies were listed among stocks that were up during an early market snapshot; AST SpaceMobile was up about 10%.
Later, Rocket Lab was described as part of a “dog recovery day.” No company-specific analysis was offered for the others.
Takeaways
These were market-movement mentions, not investment recommendations. The transcript provides no price targets or company-specific catalysts to assess.
Zscaler (ZS), Datadog (DDOG), and Cloudflare (NET)
The speaker said these stocks “want to break out,” expressing a positive near-term chart or momentum view.
Takeaways
This is a brief, momentum-oriented comment rather than a detailed fundamental thesis. No price targets or time horizon were provided.
Apple (AAPL) and OpenAI
Apple was described as up slightly during an early market snapshot.
The speaker mentioned news of a new phone from OpenAI but did not discuss a product launch timeline, likely sales, or a direct competitive impact on Apple.
Takeaways
The transcript raises a possible technology and device-competition theme but offers no basis for estimating its effect on Apple or OpenAI.
Walmart (WMT)
Walmart was down about 2% in an early market snapshot.
Takeaways
This was a market update only. The speaker gave no explanation, target, or recommendation.
StoneX (SNEX)
StoneX was down about 15% in an early market snapshot.
Takeaways
The transcript provides no explanation for the decline, so it does not support a company-specific investment conclusion.
Consumer staples: Campbell’s (CPB), General Mills (GIS), Kraft Heinz (KHC), and Colgate-Palmolive (CL)
Campbell’s, General Mills, Kraft Heinz, and Colgate-Palmolive were listed among declining consumer-staples stocks.
Takeaways
The speaker noted weakness in the staples sector but did not identify a cause or express a view on any individual company’s valuation.
Sanofi (SNY)
Sanofi was mentioned in connection with a reported potential acquisition of Insmed. The report was not confirmed in the transcript.
Takeaways
The discussion does not provide a stand-alone view on Sanofi. Any investment interpretation tied to Insmed should account for the uncertainty of the reported deal.
Summit Therapeutics (SMMT) and Capra/CAPR (company identification unclear)
The speaker said Summit had received an FDA Complete Response Letter (CRL).
He also predicted that “Capra” would announce an FDA rejection, then referred to the FDA having told the company something. The company name is unclear in the transcript; it may refer to Capricor Therapeutics (CAPR).
Takeaways
The discussion highlights FDA decisions as a key risk for these biotech names, but the “Capra” identification and the prediction are uncertain.
The comments are not a substitute for confirming the regulatory status directly. No price target or specific trade recommendation was provided.
A viewer prompted the speaker to “short TVTX.” The speaker did not clearly endorse that suggestion; he responded that NVIDIA could be valued like any other stock and then moved on.
Takeaways
Do not treat the viewer’s short suggestion as the speaker’s recommendation. The transcript provides no developed investment case for TVTX.
Hyperliquid and perpetual futures
The speaker described Hyperliquid as a venue for perpetual futures and said he did not own Hyperliquid.
He discussed Anthropic perpetual futures trading around $103–$105, with roughly $340 million in volume over the prior 24 hours. He also mentioned that trading the perpetual product required a VPN.
Takeaways
Perpetual futures were being used as a short-term signal for the expected Anthropic opening price, not as proof of the company’s fair value.
The speaker said he did not own Hyperliquid. The transcript does not provide an investment thesis or price target for the platform or its token.
Distressed credit and CDS
The speaker reviewed CDS spreads and described Virgin Media Finance as already bankrupt.
He said CoreWeave had a default probability similar to Argentina’s. Other names mentioned among higher-spread or distressed credits included Goodyear Tire, Bausch Health, R.R. Donnelley, Unisys, Beazer, American Airlines, Paramount, Warner Bros. Discovery, and Walgreens.
He also listed sovereign credits including Argentina, Angola, Kenya, Pakistan, and Ecuador.
Takeaways
The discussion identifies these names as credit-risk monitoring items, not as recommended investments. High CDS spreads can reflect elevated perceived default risk.
The speaker did not give recovery estimates, bond recommendations, or specific CDS trade levels.
Ask about this postAnswers are grounded in this post's content.
Video Description
🔴 USE CODE: THESHKRELIPILL for 30% OFF! https://app.godelterminal.com/?via=theshkrelipill
► I'm Selling Eli Lilly on the News. Big Short in the Making: Capricor CAPR Stock https://youtu.be/khuTLCrerHA
► 60% of Coachella Tickets Were Financed. My Stock Positions | Lowe's Stock, Arvinas https://youtu.be/B5OSkRlqYTQ
► Buying Peak Cycle Traps You in a Good Stock for 10 Years | AMAT Applied Materials https://youtu.be/QLjsQgliSNY
📖 [𝗠𝗔𝗥𝗧𝗜𝗡'𝗦 𝗕𝗢𝗢𝗞 𝗥𝗘𝗖𝗢𝗠𝗠𝗘𝗡𝗗𝗔𝗧𝗜𝗢𝗡𝗦 𝗙𝗥𝗢𝗠 𝗛𝗜𝗦 𝗟𝗜𝗩𝗘𝗦𝗧𝗥𝗘𝗔𝗠𝗦]
𝗙𝗨𝗟𝗟 𝗟𝗜𝗦𝗧 👉 https://pastebin.com/XiG8KHd6
📖 𝐁𝐫𝐲𝐚𝐧 𝐁𝐮𝐫𝐫𝐨𝐮𝐠𝐡: 𝐁𝐚𝐫𝐛𝐚𝐫𝐢𝐚𝐧𝐬 𝐚𝐭 𝐭𝐡𝐞 𝐆𝐚𝐭𝐞: 𝐓𝐡𝐞 𝐈𝐧𝐬𝐢𝐝𝐞 𝐒𝐭𝐨𝐫𝐲 𝐨𝐟 𝐀𝐦𝐞𝐫𝐢𝐜𝐚’𝐬 𝐌𝐨𝐬𝐭 𝐍𝐨𝐭𝐨𝐫𝐢𝐨𝐮𝐬 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐓𝐚𝐤𝐞𝐨𝐯𝐞𝐫
[BOOK] https://amzn.to/4gZk9SR
[KINDLE] https://amzn.to/46Kkky9
[FREE AUDIO W/ FREE TRIAL] https://amzn.to/4gXeI6U
📖 𝐌𝐨𝐫𝐫𝐢𝐬 𝐓𝐞𝐧𝐞𝐧𝐛𝐚𝐮𝐦: 𝐎𝐫𝐝𝐢𝐧𝐚𝐫𝐲 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐢𝐚𝐥 𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧𝐬
[BOOK] https://amzn.to/3WvhSW4
📖 𝐑𝐨𝐠𝐞𝐫 𝐋𝐨𝐰𝐞𝐧𝐬𝐭𝐞𝐢𝐧: 𝐖𝐡𝐞𝐧 𝐆𝐞𝐧𝐢𝐮𝐬 𝐅𝐚𝐢𝐥𝐞𝐝: 𝐓𝐡𝐞 𝐑𝐢𝐬𝐞 𝐚𝐧𝐝 𝐅𝐚𝐥𝐥 𝐨𝐟 𝐋𝐨𝐧𝐠-𝐓𝐞𝐫𝐦 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭
[BOOK] https://amzn.to/4mROCn9
[KINDLE]https://amzn.to/4o8EW8X
[FREE AUDIO W/ FREE TRIAL] https://amzn.to/4nGl4dp
[𝗢𝗥𝗜𝗚𝗜𝗡𝗔𝗟 𝗩𝗜𝗗𝗘𝗢]
https://www.youtube.com/watch?v=xJfAGIeEbd0
[𝗧𝗜𝗠𝗘𝗦𝗧𝗔𝗠𝗣𝗦] | [💎] = tips, advice, gems
00:00 [💎] Anthropic IPO: Is a $2 Trillion Valuation Justified?
03:54 [💎] What Is Anthropic Actually Worth?
04:18 Can Anthropic Keep Growing Revenue 10x a Year?
06:17 [💎] Being Bullish on AI Doesn't Mean Every AI Stock Is a Buy
07:09 Why Distressed Debt Investors Buy Bankrupt Companies
08:40 Trading Anthropic's IPO Before the Stock Market Opens
09:00 Where Does Wall Street Get Its Market Data?
11:25 The Anthropic IPO Countdown Begins
12:09 SanDisk (SNDK) Is Up 20% Already This Year
12:23 Trading Anthropic in Real Time: $103 or $140?
13:44 Why the Anthropic IPO Opening Price Matters
14:20 What Is Anthropic's (ANTHROPIC) Competitive Moat?
14:33 Sanofi (SNY) Makes a Move on a Beaten-Down Biotech Stock
14:57 [💎] Rare Disease Stocks: The Value Investing Opportunity
15:06 Wall Street's IPO Underwriters Are Getting It Right
16:04 [💎] Anthropic IPO Finally Opens: The First Trades
17:12 A Brutal Reversal in Market Sentiment
17:54 The Best Stock Picks in the Contest Are All Shorts
18:53 Can FPGAs Actually Beat GPUs?
19:18 [💎] Nvidia (NVDA) Guidance Could Change Everything
20:35 Is Micron (MU) Still a Buy?
21:21 One Bad Semiconductor Guidance Could Crash the Entire Sector
22:14 Photonic Computing: The Next AI Hardware Breakthrough?
22:47 Why Companies Could Deliver Disappointing Guidance
23:31 FDA Rejections Are Becoming a Major Biotech Risk
23:50 Nvidia (NVDA) Can Be Valued Like Any Other Stock
23:58 The AI Infrastructure Bull Case Is Starting to Change
24:06 Google (GOOGL) Doesn't Need Nvidia GPUs for Gemini
24:33 Anthropic IPO: Is the Public Market Price Worth Paying?
24:38 [💎] Nvidia (NVDA) Drops as the Market Turns Red
26:20 The Market Carnage Is Spreading Across Tech
26:34 [💎] Which Companies Have the Highest Risk of Default?
[𝗠𝗔𝗥𝗧𝗜𝗡'𝗦 𝗢𝗙𝗙𝗜𝗖𝗜𝗔𝗟 𝗬𝗢𝗨𝗧𝗨𝗕𝗘 𝗖𝗛𝗔𝗡𝗡𝗘𝗟𝗦]
🔴 𝗙𝘂𝗹𝗹 𝗟𝗶𝘃𝗲𝘀𝘁𝗿𝗲𝗮𝗺𝘀 𝗛𝗲𝗿𝗲: @realmartinshkreli
https://www.youtube.com/@realmartinshkreli/streams
🔴 𝗠𝗮𝗿𝘁𝗶𝗻'𝘀 𝗙𝗶𝗻𝗮𝗻𝗰𝗲 & 𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 𝗟𝗲𝘀𝘀𝗼𝗻𝘀 @mrmartinshkreli8223
https://www.youtube.com/@mrmartinshkreli8223/videos
[𝗦𝗢𝗖𝗜𝗔𝗟𝗦]
𝗦𝗵𝗸𝗿𝗲𝗹𝗶'𝘀 𝗦𝗼𝗰𝗶𝗮𝗹: https://linktr.ee/martinshkreli
𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗛𝗶𝘀 𝗦𝘁𝗿𝗲𝗮𝗺: https://streamlabs.com/martinshkreli2
𝗪𝗲𝗯𝘀𝗶𝘁𝗲: http://www.martinshkreli.com/
𝗚𝗶𝘁𝗵𝘂𝗯: https://github.com/martinshkreli
[𝗣𝗟𝗔𝗬𝗟𝗜𝗦𝗧𝗦]
https://www.youtube.com/@TheShkreliPill/playlists
[𝗙𝗜𝗡𝗔𝗡𝗖𝗘 𝗔𝗡𝗗 𝗜𝗡𝗩𝗘𝗦𝗧𝗜𝗡𝗚 𝗖𝗟𝗔𝗦𝗦 [𝟮𝟬𝟭𝟲] 𝗧𝗜𝗠𝗘𝗦𝗧𝗔𝗠𝗣𝗦 𝗔𝗡𝗗 𝗘𝗗𝗜𝗧𝗘𝗗]
https://www.youtube.com/playlist?list=PLBfupwmfhBrWnPtx_5Nm4OvhqmRXdD9AF
[𝗕𝗘𝗦𝗧 𝗢𝗙 𝗠𝗔𝗥𝗧𝗜𝗡 𝗦𝗛𝗞𝗥𝗘𝗟𝗜: 𝗜𝗱𝗲𝗮𝘀 & 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀]
https://www.youtube.com/watch?v=M2aRJ4ljm0o&list=PLBfupwmfhBrVjLr-lRNa_tDjVatMA9S9d&index=19
[𝗢𝗣𝗧𝗜𝗢𝗡𝗦 𝗔𝗡𝗗 𝗦𝗛𝗢𝗥𝗧𝗜𝗡𝗚 𝗦𝗧𝗥𝗔𝗧𝗘𝗚𝗜𝗘𝗦 | 𝗠𝗮𝗿𝘁𝗶𝗻 𝗦𝗵𝗸𝗿𝗲𝗹𝗶]
https://www.youtube.com/playlist?list=PLBfupwmfhBrUm2y3lLiKSN4FDmly5vipV
[𝗗𝗥𝗨𝗚 𝗗𝗜𝗦𝗖𝗢𝗩𝗘𝗥𝗬 𝗣𝗥𝗢𝗖𝗘𝗦𝗦 & 𝗣𝗔𝗧𝗘𝗡𝗧 𝗗𝗨𝗥𝗔𝗧𝗜𝗢𝗡𝗦]
https://www.youtube.com/playlist?list=PLBfupwmfhBrU5M3f2OZ2BhPnaQyGwnnYn
[𝗜𝗡𝗩𝗘𝗦𝗧𝗜𝗡𝗚 & 𝗙𝗜𝗡𝗔𝗡𝗖𝗜𝗔𝗟 𝗟𝗘𝗦𝗦𝗢𝗡𝗦]
https://www.youtube.com/watch?v=yZMHBcQncgk&list=PLBfupwmfhBrXbXbKHdmk9nzjnO77Ok5qn&index=9
[𝗧𝗵𝗲 𝗙𝗧𝗫 / 𝗖𝗿𝘆𝗽𝘁𝗼 𝗖𝗿𝗮𝘀𝗵 𝗘𝗿𝗮 [𝟮𝟬𝟮𝟮] | 𝗠𝗮𝗿𝘁𝗶𝗻 𝗦𝗵𝗸𝗿𝗲𝗹𝗶]
https://www.youtube.com/watch?v=jklylG7pBF0&list=PLBfupwmfhBrWq8DwWFcnzKPf42WJtJ3Kd&index=4
[ ! ] The videos on my YouTube channel include material from Martin Shkreli’s livestreams. The use of the video material is authorized by Martin Shkreli
Any video material that appears identically in uploads from other YouTube channels is purely coincidental. I have no control over or ownership of such reuploads and am not aware of their relationship with the original creator.
[𝗔𝗙𝗙𝗜𝗟𝗜𝗔𝗧𝗘 𝗟𝗜𝗡𝗞 𝗗𝗜𝗦𝗖𝗟𝗔𝗜𝗠𝗘𝗥]
Amazon links above include affiliate commission or referrals.
I'm part of an affiliate network and I receive compensation from partnering website.
By purchasing product through this link you help supporting this channel.